Clinical Trials Logo

Clinical Trial Summary

Adults hospitalized in psychiatry have an increased frequency of somatic disorders, in particular various liver diseases (viral hepatitis, non-alcohol related liver steatosis, alcohol related liver disease). The evaluation of these liver disorders in psychiatric inpatients remains very little explored in France, contributing to the poor overall medical status of psychiatric patients. The LIVERSPIN study aims to estimate the prevalence rates of liver pathologies in psychiatric inpatients and to explore the factors associated with the existence of a liver pathology


Clinical Trial Description

The LIVERSPIN study aims to estimate the prevalence rates of liver disease in psychiatric inpatients and to explore factors associated with the existence of liver disease. All hospitalized patients can potentially be recruited. They will benefit from the usual clinical and paraclinical examinations as part of their hospitalization diagnostic work-up. For the determination of biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05213442
Study type Interventional
Source Hôpital le Vinatier
Contact Benjamin ROLLAND, MD, PhD
Phone +33 437 915 555
Email [email protected]
Status Recruiting
Phase N/A
Start date April 6, 2022
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05133726 - Peer and Text Message Support to Reduce Readmission Rates for Patients Discharged From Acute Psychiatric Care N/A
Completed NCT01623505 - Reducing Cardiovascular Disease by Combining Smoking Cessation Pharmacotherapy and Behavioural Counseling Phase 4
Completed NCT05119946 - A Feasibility Study of a Suicide Prevention Video N/A
Active, not recruiting NCT04336605 - Killing Pain - Use of Analgesic, Sedative and Anxiolytic Medication and the Development of Psychiatric Illness in Adolescents
Not yet recruiting NCT03327129 - Identifying the Neural Basis of Capability for Suicide
Recruiting NCT03184597 - HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions N/A